glp-1 papillary thyroid cancer receptor agonist use for more than 1 year may increase risk GLP-1RA and thyroid cancer: New

Description

The participants received weekly 2-milligram injections for six weeks, and the results were encouraging

Labs required before prescription approval

Nonetheless, the class is contraindicated in patients with a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN2) as a precaution

Patients should be advised to contact their GP urgently if hair loss is accompanied by scalp pain, redness, scaling, or loss of follicular openings, as these may indicate scarring alopecia requiring prompt dermatological assessment

GLP-1 agonist drugs like semaglutide (brand: Ozempic, Rybelsus) and tirzepatide (brand: Mounjaro) have been making waves in western markets, particularly the United States, over the past year as weight loss drugs, with major impacts expected for the food industry due to their appetite-suppressing capabilities